crystal arthropathies
Recently Published Documents


TOTAL DOCUMENTS

54
(FIVE YEARS 2)

H-INDEX

5
(FIVE YEARS 0)

Medicine ◽  
2021 ◽  
Author(s):  
Sean Y.W. Tan ◽  
James Stanway ◽  
Spencer Ellis

Author(s):  
Yessica Zamudio-Cuevas ◽  
Gabriela Angélica Martínez-Nava ◽  
Karina Martínez-Flores ◽  
Lucio Ventura-Ríos ◽  
Janitzia Vazquez-Mellado ◽  
...  

2020 ◽  
Vol 15 (10) ◽  
pp. 1773-1776
Author(s):  
Antonio Catelli ◽  
Pietro Venetucci ◽  
Anna Castaldo ◽  
Giovanni loiudice ◽  
Filippo Rosati Tarulli ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Mohaned Hameed ◽  
Aleksandra Turkiewicz ◽  
Martin Englund ◽  
Lennart Jacobsson ◽  
Meliha C. Kapetanovic

Abstract Objective To estimate the prevalence and incidence of non-gout crystal arthropathy in relation to socioeconomic factors in southern Sweden. Methods All patients (age ≥ 18 years) with at least one visit to a physician with the diagnosis of interest in the Skåne region (population of 1.3 million) in 1998–2014 were identified. Non-gout crystal arthropathy (ICD-10 codes M11.0–M11.9) was subclassified in four different groups: calcium pyrophosphate crystal deposition related arthropathy (CPPD), unspecified non-gout arthropathies, chondrocalcinosis, and hydroxyapatite crystal deposition disease. The crude and age-adjusted point prevalence on December 31, 2014, and the cumulative incidence during 2014 were calculated for all non-gout crystal arthropathies, CPPD, and other unspecified non-gout arthropathies overall and in relation to occupation, income, and level of education. Results The crude 2014 point prevalence (95% CI) and 2014 cumulative incidence (95% CI) of all non-gout crystal arthropathies were 0.23% (0.23–0.24) and 21.5 (19–25) cases/100,000 persons. Mean age (range) among all prevalent cases in 2014 was 71 (20–102) years and 56% were males. The point prevalence and cumulative incidence of CPPD were 0.09% (0.08–0.09) and 8 (7–10)/100,000 persons, respectively. The corresponding data for unspecified non-gout crystal deposition disease was 0.16% (0.16–0.17) and 15.6 (13–18)/100,000 persons, respectively. The prevalence and incidence of CPPD and unspecified non-gout crystal arthropathies were slightly higher in men and increased with age irrespective of gender. Unspecified non-gout crystal arthropathy but not CPPD was less prevalent in persons with ≥ 15 years of education, whereas there were no clear associations with occupation and income. Conclusion The prevalence of all diagnosed non-gout crystal arthropathies was 0.23%, thus considerably less prevalent than gout in southern Sweden. CPPD and other unspecified non-gout crystal arthropathies are the predominant diagnoses, increasing with age and in men. With the exception for unspecified non-gout crystal arthropathies being inversely correlated to a higher level of education, no convincing association with the socioeconomic factors was found.


Author(s):  
Eleftherios Pelechas ◽  
Evripidis Kaltsonoudis ◽  
Paraskevi V. Voulgari ◽  
Alexandros A. Drosos

2018 ◽  
Vol 143 (16) ◽  
pp. 1157-1166 ◽  
Author(s):  
Monika Reuss-Borst ◽  
Anne-Kathrin Tausche

AbstractThe metabolic diseases gout and calciumpyrophosphate deposition (CPPD) (formerly: chondrocalcinosis/pseudogout) are crystal arthropathies which are caused by crystals in synovial fluid and in the case of gout also in periarticular structures. Today, in particular gout is considered as an auto-inflammatory process since phagocytosis of monosodium urate crystals by monocytes/macrophages results in the activation of the innate immune system by activation of the NRLP3-Inflammasome and consecutive secretion of the key cytokine interleukin-1ß and other pro-inflammatory cytokines. The prevalence of both crystal arthropathies rises with increasing age of patients. Most often they present clinically as an acute monarthritis of different locations. Beside typical clinical presentation, performance of ultrasonography, conventional X-Ray of joints and under special circumstances dual-energy-computer tomography could be also helpful diagnostic tools. There are EULAR guidelines describing the diagnostic algorithm for making right diagnosis. The arthrocentesis with microscopic detection of crystals is established diagnostic gold standard. Whereas crystals of monosodium urate could be very clearly be seen as relatively large intra- and extracellular needles with a strong birefringence in polarized light microscopy the detection of CPPD-crystals is more difficult. Those crystals are much smaller, showing weaker birefringence and are sometimes only seen with ordinary light microscopy. As both crystal diseases are mediated by IL-1 driven processes, the therapeutic intervention first target the acute inflammation consisting in colchicine, NSAIDs and glucocorticoids. Secondarily, in gout there are well established causal therapies to lower effectively serum urate levels below the target of 6 mg/dL (360 µmol/l). Unfortunately, those causal therapeutic options are still lacking in CPPD.


2018 ◽  
Vol 22 (02) ◽  
pp. 225-236 ◽  
Author(s):  
Fiona McQueen ◽  
Iris Eshed ◽  
Athena Plagou ◽  
Andrea Klauser ◽  
James Teh

AbstractIn recent years significant advances have been made in imaging techniques. Dual-energy computed tomography has revolutionized the ability to detect and quantify gout. The key ultrasound features of gout have been defined. Magnetic resonance imaging is an excellent modality for demonstrating the extent and severity of crystal arthropathies, but the findings may be nonspecific. This article summarizes the use of advanced imaging techniques in the diagnosis and assessment of gout and other crystal arthropathies.


Medicine ◽  
2018 ◽  
Vol 46 (3) ◽  
pp. 181-186 ◽  
Author(s):  
James Stanway ◽  
Thiraupathy Marianayagam ◽  
Spencer Ellis

Sign in / Sign up

Export Citation Format

Share Document